Your browser doesn't support javascript.
loading
Saccharomyces boulardii as an adjuvant therapy for Helicobacter pylori eradication: A systematic review and meta-analysis with trial sequential analysis.
Zhou, Ben-Gang; Chen, Ling-Xiao; Li, Bo; Wan, Lin-Yan; Ai, Yao-Wei.
Afiliação
  • Zhou BG; Department of Gastroenterology, The People's Hospital of China Three Gorges University and The First People's Hospital of Yichang, Yichang, China.
  • Chen LX; Institute of Bone and Joint Research, Kolling Institute, Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
  • Li B; Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing Institute of Traditional Chinese Medicine, Beijing, China.
  • Wan LY; Department of Gastroenterology, The People's Hospital of China Three Gorges University and The First People's Hospital of Yichang, Yichang, China.
  • Ai YW; Department of Gastroenterology, The People's Hospital of China Three Gorges University and The First People's Hospital of Yichang, Yichang, China.
Helicobacter ; 24(5): e12651, 2019 Oct.
Article em En | MEDLINE | ID: mdl-31414551
ABSTRACT
BACKGROUND AND

AIMS:

Whether Saccharomyces boulardii (S boulardii) as an adjuvant therapy are beneficial to H pylori eradication remains controversial. The aim of the study was to update and determine the effects of S boulardii as an adjuvant therapy on H pylori eradication rates and adverse effects.

METHODS:

We searched PubMed, Embase, CENTRAL, and Web of Science to collect all randomized controlled trials assessing the effects of S boulardii as an adjuvant therapy for H pylori eradication from inception to February 2019. Quality of evidence was appraised using Grading of Recommendations, Assessment, Development and Evaluation system. Trial sequential analysis was performed to control the risk of type I and type II errors.

RESULTS:

Eighteen trials with 3592 patients were eligible for meta-analysis. Compared with standard eradication regimen, the S boulardii supplementation could significantly improve eradication rates [risk ratio (RR) = 1.09, 95% confidence interval (CI)1.05-1.13; moderate quality evidence] and reduce the incidence of total side effects (RR = 0.47, 95%CI0.36-0.61; low quality evidence), as well as some gastrointestinal adverse effects, especially diarrhea (RR = 0.33, 95%CI0.23-0.47; low quality evidence) and constipation (RR = 0.37, 95%CI0.23-0.57; moderate quality evidence). In addition, the need for discontinuation rate in S boulardii supplementation group was significantly lower than in the control group (RR = 0.33, 95%CI0.16-0.69, P = .003; moderate quality evidence). The TSA results for overall eradication rates and total side effects indicated that the effects were conclusive.

CONCLUSIONS:

Our meta-analysis shows that S boulardii supplementation on standard eradication therapy significantly increased H pylori eradication rates and reduced the incidence of total side effects and some gastrointestinal adverse effects during eradication therapy.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 3_ND Base de dados: MEDLINE Assunto principal: Infecções por Helicobacter / Probióticos / Inibidores da Bomba de Prótons / Saccharomyces boulardii / Antibacterianos Tipo de estudo: Clinical_trials / Guideline / Systematic_reviews Limite: Adolescent / Adult / Aged / Aged80 / Child / Child, preschool / Female / Humans / Infant / Male Idioma: En Revista: Helicobacter Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 3_ND Base de dados: MEDLINE Assunto principal: Infecções por Helicobacter / Probióticos / Inibidores da Bomba de Prótons / Saccharomyces boulardii / Antibacterianos Tipo de estudo: Clinical_trials / Guideline / Systematic_reviews Limite: Adolescent / Adult / Aged / Aged80 / Child / Child, preschool / Female / Humans / Infant / Male Idioma: En Revista: Helicobacter Ano de publicação: 2019 Tipo de documento: Article